Neuroimmunological Aspects in Glaucoma

Abstract

Glaucoma pathogenesis hast still to be elucidated. Next to its main risk factor, an increased intraocular pressure, an e.g. altered biomechanics of the lamina cribrosa, oxidative stress-mediated changes and glutatmate toxicity are involved in this multifactorial pathophysiology. Recent experimental studies and clinical findings suggest an involvement of the immune system in glaucoma. This review will give an overview of the different immunologic aspects being involved in glaucoma pathogenesis.

Key words

glaucoma - immune system - autoantibody

• References/Literatur

• 1 Hohberger B, Monczak E, Mardin CY. [26 years of the Erlangen glaucoma registry: demographic and perimetric characteristics of patients through the ages]. Klin Monbl Augenheilkd 2019; 236: 691-698 doi:10.1055/s-0043-112856
• 2 Erb C. [Secondary neuroprotection in glaucoma through the concepts of complementary drug therapy]. Klin Monbl Augenheilkd 2020; 237: 163-174 doi:10.1055/a-1093-0945
• 3 Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 2006; 25: 490-513 doi:10.1016/j.preteyeres.2006.07.003
• 4 Aroca-Aguilar JD, Fernandez-Navarro A, Ontanon J. et al. Identification of myocilin as a blood plasma protein and analysis of its role in leukocyte adhesion to endothelial cell monolayers. PLoS One 2018; 13: e0209364 doi:10.1371/journal.pone.0209364
• 5 Hohberger B, Harazny J, Laemmer R. et al. Influence of agonistic β2-adrenergic receptor autoantibodies on retinal capillary flow in ocular hypertension and open-angle glaucoma. Invest Ophthalmol Vis Sci 2015; 56: 2748
• 6 Mardin CY, Hosari S, Wallukat G. et al. OCT-Angiography: agonistic β2-adrenergic receptor autoantibodies and FAZ-to-FAZ-ratio in glaucoma patients. Invest Ophthalmol Vis Sci 2019; 60: 6158
• 7 Becker S, Reinehr S, Dick HB. et al. [Complement activation after induction of ocular hypertension in an animal model]. Ophthalmologe 2015; 112: 41-48 doi:10.1007/s00347-014-3100-6
• 8 Wax MB, Tezel G. Immunoregulation of retinal ganglion cell fate in glaucoma. Exp Eye Res 2009; 88: 825-830 doi:10.1016/j.exer.2009.02.005
• 9 Wax MB. The case for autoimmunity in glaucoma. Exp Eye Res 2011; 93: 187-190 doi:10.1016/j.exer.2010.08.016
• 10 Chen H, Cho KS, Vu THK. et al. Commensal microflora-induced T cell responses mediate progressive neurodegeneration in glaucoma. Nat Commun 2018; 9: 3209 doi:10.1038/s41467-018-05681-9
• 11 Wax MB, Tezel G, Yang J. et al. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci 2008; 28: 12085-12096 doi:10.1523/JNEUROSCI.3200-08.2008
• 12 Joachim SC, Wax MB, Seidel P. et al. Enhanced characterization of serum autoantibody reactivity following HSP 60 immunization in a rat model of experimental autoimmune glaucoma. Curr Eye Res 2010; 35: 900-908 doi:10.3109/02713683.2010.495829
• 13 Zhang X, Clark AF, Yorio T. Heat shock protein 90 is an essential molecular chaperone for nuclear transport of glucocorticoid receptor beta. Invest Ophthalmol Vis Sci 2006; 47: 700-708 doi:10.1167/iovs.05-0697
• 14 Joachim SC, Pfeiffer N, Grus FH. Autoantibodies in patients with glaucoma: a comparison of IgG serum antibodies against retinal, optic nerve, and optic nerve head antigens. Graefes Arch Clin Exp Ophthalmol 2005; 243: 817-823 doi:10.1007/s00417-004-1094-5
• 15 Tezel G, Edward DP, Wax MB. Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Arch Ophthal 1999; 117: 917-924 doi:10.1001/archopht.117.7.917
• 16 Yano T, Yamada K, Kimura A. et al. Autoimmunity against neurofilament protein and its possible association with HLA-DRB1*1502 allele inglaucoma. Immunol Lett 2005; 100: 164-169 doi:10.1016/j.imlet.2005.03.017
• 17 Kremmer S, Kreuzfelder E, Klein R. et al. Antiphosphatidylserine antibodies are elevated in normal tension glaucoma. Clin Exp Immunol 2001; 125: 211-215 doi:10.1046/j.1365-2249.2001.01578.x
• 18 Maruyama I, Ohguro H, Ikeda Y. Retinal ganglion cells recognized by serum autoantibody against gamma-enolase found in glaucoma patients. Invest Ophthalmol Vis Sci 2000; 41: 1657-1665
• 19 Yang J, Patil RV, Yu H. et al. T cell subsets and sIL-2R/IL-2 levels in patients with glaucoma. Am J Ophthalmol 2001; 131: 421-426 doi:10.1016/s0002-9394(00)00862-x
• 20 Nakazawa T, Nakazawa C, Matsubara A. et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006; 26: 12633-12641 doi:10.1523/JNEUROSCI.2801-06.2006
• 21 Tilch DA, Schäfer HG, Winter R. [Diagnostics of Sjögrenʼs syndrome by means of anti-alpha-fodrin antibody]. Klin Monbl Augenheilkd 2007; 224: 427-430 doi:10.1055/s-2007-963097
• 22 Grus FH, Joachim SC, Bruns K. et al. Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest Ophthalmol Vis Sci 2006; 47: 968-976 doi:10.1167/iovs.05-0685
• 23 Fel A, Aslangul E, Le Jeunne C. Indications et complications des corticoïdes en ophtalmologie. Presse Med 2012; 41: 414-421
• 24 Carli L, Tani C, Querci F. et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologistsʼ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol 2013; 32: 1071-1073 doi:10.1007/s10067-013-2214-6
• 25 Samuels BC, Hammes NM, Johnson PL. et al. Dorsomedial/perifornical hypothalamic stimulation increases intraocular pressure, intracranial pressure, and the translaminar pressure gradient. Invest Ophthalmol Vis Sci 2012; 53: 7328-7335 doi:10.1167/iovs.12-10632
• 26 Junemann A, Hohberger B, Rech J. et al. Agonistic autoantibodies to the beta2-adrenergic receptor involved in the pathogenesis of open-angle glaucoma. Front Immunol 2018; 9: 145 doi:10.3389/fimmu.2018.00145
• 27 Hohberger B, Kunze R, Wallukat G. et al. Autoantibodies activating the beta2-adrenergic receptor characterize patients with primary and secondary glaucoma. Front Immunol 2019; 10: 2112 doi:10.3389/fimmu.2019.02112